HemaQuest Initiates Phase I Blood Diseases Trial
Posted on: Friday, 18 January 2008, 09:00 CST
HemaQuest Pharmaceuticals has reported that following FDA's acceptance of its investigational new drug application, it has started a Phase I clinical trial of its orally administered, patented therapeutic, HQK-1001 that is being developed to treat the two most common inherited blood diseases, sickle cell anemia and thalassemia.
The Phase I clinical study is being carried out in healthy volunteers, who will receive increasing doses of HQK-1001 to evaluate its safety and pharmacokinetics in anticipation of future clinical trials in patients with these hemoglobin disorders.
Ronald Berenson, president and CEO of HemaQuest, said: "We are committed to continuing the rapid development path for HQK-1001, which has the potential to be a major advance in treating serious and life-threatening blood disorders."
Source: Datamonitor
Related Articles
- Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
- HemaQuest Wins Orphan Drug Designations for Anemia Drug
- HemaQuest Pharmaceuticals Receives Orphan Drug Designations for Therapeutic to Treat Hemoglobin Disorders
- Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
- HemaQuest Announces Initiation of Phase I Clinical Trial of HQK-1001 to Treat Hemoglobin Disorders
- Alba Therapeutics Announces Phase IIb Clinical Trial for Oral AT-1001 for the Treatment of Celiac Disease
- Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
- Alba Announces Completion of Enrollment and Dosing of Patients in Phase II Clinical Trial of AT-1001 for the Treatment of Celiac Disease
- Abeille Initiates Phase I Clinical Trial of AB-1001 for Prevention of Emesis Associated With Chemo- and Radiation Therapy
 |
 |
User Comments (0)
RSS Feeds